Gilotrif (Afatinib) is a newly approved targeted cancer therapy for the treatment of advanced lung cancer, such as metastatic non-small cell lung cancer. that is EGFR positive. Taken as a pill, Gilotrif treats people with cancers that have a genetic mutation in a gene called epidermal growth factor receptor (EGFR). Medical oncologist Stephen Lemon MD-MPH provides an overview on this promising new lung cancer drug. At the recent ASCO (American Society of Clinical Oncology) conference, a new study showed that Gilotrif improved the overall survival in a single subset of advanced non-small cell lung cancers.
CancerIS produces videos to help provide useful cancer information to cancer patients and caregivers. CancerIS.net is an online resource to find and share any information regarding cancer. Please visit CancerIS.net to learn more.